

## Subset Analyses From the VMAC Trial

### Impact of Treatment on Outcomes and Pharmacoeconomic Variables

THE CLEVELAND CLINIC  
FOUNDATION

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---



## VMAC and Acute Coronary Syndrome (ACS)

61 VMAC patients with ACS

- ACS defined as:
  - ECG or marker changes, USA
  - PTCA, CABG, CVS, death
- Intervention:
  - Std tx with NTG or nesiritide
- Demographics
  - Mean age 63.6 y, 54% male, mean EF 34%
  - 43% white, 34% Hispanic, 15% Afr Am

THE CLEVELAND CLINIC  
FOUNDATION

Peacock WF, et al. J Card Fail. 2002;8(suppl):S49.

---

---

---

---

---

---

---

---



## VMAC and ACS: Nesiritide vs NTG

No statistically significant differences in:

- **Mortality**  
( $p > 0.05$ )
- **PCWP**  
( $p > 0.05$ )
- **Hypotension rates**  
( $p > 0.05$ )

THE CLEVELAND CLINIC  
FOUNDATION

Peacock WF, et al. *J Card Fail.* 2002;8(suppl):S49.

---

---

---


---

---

---

---

---



## VMAC and ACS: Dyspnea

### Non-catheterized group

Markedly or moderately improved dyspnea at 24 hours

- Nesiritide 75% ( $p = 0.031$ )
- NTG 55%

At least minimally better at 24 hours

- Nesiritide 100% ( $p = 0.031$ )
- NTG 71%

Markedly or moderately improved global clinical status

At 6 hours

- Nesiritide 75% ( $p = 0.031$ )
- NTG 32%

At 24 hours

- Nesiritide 75% ( $p = 0.029$ )
- NTG 52%

THE CLEVELAND CLINIC  
FOUNDATION

Peacock WF, et al. *J Card Fail.* 2002;8(suppl):S49.

---

---

---

---

---

---

---

---



## VMAC and ACS: Readmits

	NTG	Nesiritide	P-value
Overall 30-day readmit	19%	8%	0.449
Overall multiple 30-day readmits	20%	8%	0.305
No PAC: 30-day readmit	17%	0%	0.276

THE CLEVELAND CLINIC  
FOUNDATION

Peacock WF, et al. *J Card Fail.* 2002;8(suppl):S49.

---

---

---

---

---

---

---

---



## Nesiritide and Renal Failure

- VMAC
  - n=489
  - Creatinine >2.0 mg/dL
- Results: n=104
  - 35 nitroglycerin
  - 43 nesiritide
  - 26 placebo

THE CLEVELAND CLINIC  
FOUNDATION

Butler J, et al. *Circulation*. 2002;106(19):II-567.

---

---

---


---

---

---

---

---



## Nesiritide and Renal Failure

- Safety profiles similar
- Symptomatic hypotension
  - 0% NTG
  - 3% nesiritide (p=NS)
- Headache
  - 16% NTG
  - 3% nesiritide (p=0.034)

THE CLEVELAND CLINIC  
FOUNDATION

Butler J, et al. *Circulation*. 2002;106(19):II-567.

---

---

---


---

---

---

---

---



## Renal Failure and Nesiritide Effect on PCWP

Time	Nesiritide	Nitro	Standard Therapy
15 Minutes	-1.7 ± 3.66 p=0.02	-1.1 ± 3.61 p=NS	-0.0 ± 4.242 p=NS
3 Hours	-6.6 ± 5.72 p=0.001	-2.9 ± 6.4 p=NS	-2.7 ± 3.46 p=0.05

THE CLEVELAND CLINIC  
FOUNDATION

Butler J, et al. *Circulation*. 2002;106(19):II-567.

---

---

---

---

---

---

---

---



## Renal Failure and Nesiritide

No statistically significant differences in:

- hypotension
- clinical adverse outcomes

THE CLEVELAND CLINIC  
FOUNDATION

Butler J, et al. *Circulation*. 2002;106(19):II-567.

---

---

---

---

---

---

---

---



## VMAC: Insights From a “Real Life” Study

- Broad inclusion criteria
- Included standard background therapy
- Patients with multiple comorbidities
- Rich database for subset analysis
  - acute coronary syndrome (ACS)
  - renal insufficiency (RI)

THE CLEVELAND CLINIC  
FOUNDATION

---

---

---

---

---

---

---

---